Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

APP Pharmaceuticals Inc.

Division of Fresenius SE & Co. KGAA
www.apppharma.com

Latest From BTG PLC

Immuno-Oncology Outlook: Bavencio Leads PD-1/L1 Pack In Ovarian Cancer

Merck KGaA/Pfizer's Bavencio is likely to be the first checkpoint inhibitor to gain approval in ovarian cancer but Roche's Tecentriq is hot on its heels. The ovarian cancer pipeline boasts seven other late-stage drugs, including antibody-drug conjugates and small molecules, that are ready to ramp up competition on the market.

Clinical Trials ImmunoOncology

BTG's Louise Makin On Joining IO Agents And Localized Intervention

BTG's CEO says combining novel immuno-oncology therapies with image-guided, minimally invasive therapies could deliver treatments where needed while lowering overall treatment costs.

Business Strategies Companies

When Two Worlds Collide – BTG Brings Interventional Oncology And Immunotherapy Together

BTG's range of interventional oncology technologies puts it in an enviable position in R&D initiatives that require a holistic view across cancer and the best-targeted therapies. The UK-listed company will now take this to another level following an agreement with the Society of Interventional Oncology to explore the role of minimally invasive therapies in immuno-oncology.

ImmunoOncology Research and Development Strategies

BTG Set To Launch First Radiopaque Drug-Eluting Bead In The EU

DC Bead Lumi is designed to be loaded with doxorubicin or irinotecan to treat liver cancer while showing the treating physician where it is to improve control of transarterial chemoembolization procedures.

Cancer Innovation
See All

Company Information

  • Industry
  • Medical Devices
    • Infusion Therapy Equipment and Supplies
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Fresenius SE & Co. KGAA
  • Senior Management
  • John Ducker, Pres. & CEO
    Richard J Tajak, EVP, CFO
    Christopher Bryant, PhD, EVP, CSO
  • Contact Info
  • APP Pharmaceuticals Inc.
    Phone: (847) 413-2075
    1501 E. Woodfield Rd.
    Ste. 300 East
    Schaumburg, IL 60173
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register